HAVCR2 and breast cancer: Unlike the blockade of PD-L1, anti-PD-1 alone did not further upregulate TIM-3 and LAG-3 co-expression on CD4+CD25+FoxP3+Helios+ Tregs in the presence of breast cancer cells.